CROI 2015: Highlights of viral hepatitis therapy

Topics in Antiviral Medicine

Volumn 23, Issue 1, 2015, Pages 66-76

  Luetkemeyer, Anne F ^a   Wyles, David L ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CROI 2015; DAAs; Daclatasvir; Direct acting antivirals; HCV; Hepatitis; Hepatitis C virus; HIV; HIV HCV coinfection; Ledipasvir; Sofosbuvir

Indexed keywords

ANTIVIRUS AGENT; ASUNAPREVIR PLUS BECLABUVIR PLUS DACLATASVIR; DACLATASVIR; DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; GAMMA INTERFERON INDUCIBLE PROTEIN 10; LEDIPASVIR PLUS SOFOSBUVIR; RIBAVIRIN; SOFOSBUVIR; BENZIMIDAZOLE DERIVATIVE; BMS-790052; FLUORENE DERIVATIVE; IMIDAZOLE DERIVATIVE; LEDIPASVIR;

ANTIVIRAL RESISTANCE; CD4+ T LYMPHOCYTE; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GENOTYPE; HEMATOLOGIC DISEASE; HEPATITIS C VIRUS; HEPATITIS DELTA VIRUS; HEPATITIS E VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; LIVER CIRRHOSIS; MEN WHO HAVE SEX WITH MEN; MIXED INFECTION; PATIENT ATTITUDE; PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; RELAPSE; REVIEW; TREATMENT OUTCOME; VACCINATION; VIRUS HEPATITIS; VIRUS LOAD; VIRUS TRANSMISSION; COMBINATION DRUG THERAPY; COMPLICATION; GENETICS; HEPACIVIRUS; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; VIROLOGY;

ANTIVIRAL AGENTS; BENZIMIDAZOLES; COINFECTION; DRUG THERAPY, COMBINATION; FLUORENES; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; IMIDAZOLES; LIVER CIRRHOSIS; SOFOSBUVIR; VIRAL LOAD;

EID: 84928969376     PISSN: 21615861     EISSN: 21615853     Source Type: Journal    
DOI: None     Document Type: Review

References (17)

1. Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015;
2. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370(20):1879-1888.
3. Eley T, You X, Wang R, et al. Daclatasvir: overview of drug-drug interactions with antiretroviral agents and other common concomitant drugs [Abstract 63]. HIV DART 2014. December 9-12, 2014; Key Biscayne, Florida.
4. Sulkowski MS, Eron JJ, Wyles D, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA. 2015; 313(12):1223-1231.
5. Lawitz E, Gane EJ. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;369(7):678-679.
6. Lawitz E, Ghalib R, Rodriguez-Torres M, et al. Simeprevir plus sofosbuvir with/ without ribavirin in HCV genotype 1 prior null-responder/treatment-naive patients (COSMOS study): primary endpoint (SVR12) results in patients with Metavir F3-4 (Cohort 2) [Abstract O165]. 49th Annual Meeting of the European Association for the Study of the Liver (EASL). April 9-13, 2014; London, United Kingdom.
7. Chhatwal J, Kanwal F, Roberts MS, Dunn MA. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med. 2015;162(6): 397-406.
8. Bichoupan K, Martel-Laferriere V, Sachs D, et al. Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological response. Hepatology. 2014;60(4):1187-1195.
9. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370(16):1483-1493.
10. Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450/rombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370(17):1604-1614.
11. Lin JC, Habersetzer F, Rodriguez-Torres M, et al. Interferon gamma-induced protein 10 kinetics in treatment-naive versus treatment-experienced patients receiving interferon-free therapy for hepatitis C virus infection: implications for the innate immune response. J Infect Dis. 2014;210(12):1881-1885.
12. Wyles DL, Gutierrez JA. Importance of HCV genotype 1 subtypes for drug resistance and response to therapy. J Viral Hepat. 2014;21(4):229-240.
13. Moyer VA. Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2013;159(5): 349-357.
14. Centers for Disease Control and Prevention (CDC). Testing Recommendations for Hepatitis C Virus Infection. http://www.cdc.gov/hepatitis/HCV/GuidelinesC.htm. Accessed on March 27, 2015.
15. AASLD/IDSA/IAS-USA. Recommendations for testing, managing, and treating hepatitis C. www.hcvguidelines.org. Accessed on March 27, 2015.
16. Potsch DV, Oliveira ML, Ginuino C, et al. High rates of serological response to a modified hepatitis B vaccination schedule in HIV-infected adults subjects. Vaccine. 2010;28(6):1447-1450.
17. Fonseca MO, Pang LW, de Paula CN, Barone AA, Heloisa Lopes M. Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. Vaccine. 2005;23(22):2902-2908.